

Gonadal Insufficiency and Affecting Factors in Patients with Bone

Marrow Transplantation for Non-malign Indications in Childhood and Adolescence

Eren Er¹, Serap Aksoylar², Humay Mehdiyeva³, Gülcihan Özek², <u>Samim Özen¹</u>, Damla Gökşen¹, Şükran Darcan¹

¹Department of Pediatric Endocrinology and Diabetes, Ege University, Izmir, Turkey

²Department of Pediatric Hematology and Oncology, Bone Marrow Transplantation Unit, Faculty of Medicine, Ege University, İzmir, Turkey

³Ege University Faculty of Medicine, Department of Pediatrics, İzmir, Turkey

INTRODUCTION:

•Gonadal insufficiency is a common long-term endocrinological complication of Bone Marrow Transplantation (BMT) and is mainly associated with the chemotherapy protocol. Gonadal insufficiency is reported as 66-80% in women and 35-60% in men after BMT

AIM:

•The aim of this cross-sectional study was to investigate the frequency and the factors affecting gonadal insufficiency in cases with BMT due to non-malignant indications in children or adolescence.

METHODS:

•Between 2006 and 2016, non-malignant indications were evaluated in Pediatric Endocrinology Department after BMT,


•The effect of the primary diagnosis, age at BMT and treatment protocols used before and during BMT on gonadal insufficiency was investigated. •Gonadal insufficiency was defined as

- prepubertal stage in girls > 13 yrs and boys >14 years,
- no progression of puberty stage for more than 12 months and/or

• LH and FSH above the upper limit of the interval according to pubertal stage.

•Patients with known gonadal insufficiency prior to BMT, or who received any treatment that could cause gonadal insufficiency and chromosomal disorders were excluded

RESULTS:



- Gonadal insufficiency developed in all the patients who received at least two of the Fludarabine, Cyclophosphamide, or Busulfan
- Gonadal insufficiency developed in 4 (80%) out of 5 patients who received Fludarabine-Busulfan-Cyclophosphamide of the BMT
- Gonadal insufficiency did not develop in the 5 patients who

- Gonadal insufficiency (+): 11.23 years (5.56-16.11),
- Gonadal insufficiency (-): 6.88 years (0.57-17.01) (p=0.03)
- - Prepubertal \rightarrow 46% (12/26) gonadal insufficiency (+)
 - Puberty stage $2 \rightarrow 33\%$ (1/3) gonadal insufficiency (+)




Figure 2: Number of patients with gonadal insufficiency due to BMT




Figure 3-4: Puberty stage at the time of BMT in patients with and without gonadal insufficiency

CONCLUSION:

•Within the BMT indications, non-malignant causes are increasing and treatment protocols are changing within the years. •Gonadal insufficiency was seen at a higher rate in patients who underwent BMT due to thalassemia major. •Older age and prepubertal stage during BMT and the combination of at least two Fludarabine, Cyclophosphamide or Busulfan regimens in pre-BMT regimens increases gonadal insufficiency risk.







24%

6

5